Please login to the form below

Not currently logged in

J&J’s COVID-19 booster shows 85% effectiveness in preventing hospitalisation for COVID-19 in study

The Sisonke study was done in South Africa while Omicron was the dominant variant

Johnson and Johnson

Johnson & Johnson (J&J) has announced that new preliminary results from the South African phase 3b Sisonke study show that a booster shot of the J&J COVID-19 vaccine is 85% effective in preventing hospitalisation for COVID-19.

The study was conducted by the South African Medical Research Council (SAMRC) among healthcare workers in approximately 350 vaccination centres across all nine provinces of South Africa after Omicron became the dominant variant.

The study was done from mid-November to mid-December when, according to GISAID, an initiative that provides COVID-19 data, the dominance of the Omicron variant increased from 82% to 98% of COVID-19 cases in South Africa.

In Israel, the Beth Israel Deaconess Medical Center (BIDMC) conducted a second, separate analysis of the immune response to different vaccine regimens, which showed that J&J’s COVID-19 vaccine booster generated a 41-fold increase in neutralising antibodies and a 5-fold increase in T-cells against Omicron.

The increase in T-cells generated by the J&J vaccine may be key to explaining the high levels of effectiveness against severe COVID-19 disease and hospitalisation in the Sisonke 2 study, as the Omicron variant has been shown to escape neutralising antibodies.

Mathai Mammen, global head, Janssen Research & Development, Johnson & Johnson said: “Data from the Sisonke 2 study confirms that the Johnson & Johnson COVID-19 booster shot provides 85% effectiveness against hospitalisation in areas where Omicron is dominant. This adds to our growing body of evidence which shows that the effectiveness of the J&J COVID-19 vaccine remains strong and stable over time, including against circulating variants such as Omicron and Delta.

“We believe that the protection could be due to the robust T-cell responses induced by the Johnson & Johnson COVID-19 vaccine. Furthermore, the data suggests that Omicron is not affecting the T-cell responses generated by our vaccine.”

Glenda Gray, president and CEO of SAMRC said: “Even before you factor in the increased infectiousness of Omicron, we have to remember that healthcare workers on the frontlines are at a greatly increased risk of being affected by COVID-19 in the first place.

“We are therefore encouraged to see that boosting with the Johnson & Johnson COVID-19 vaccine regimen provides strong protection in a challenging real-world setting where there is an elevated risk of exposure – not just to COVID-19, but to the highly transmissible Omicron variant.”

The data has been submitted to the pre-print server medRxiv by the studies’ authors.

Article by
Iona Everson

4th January 2022

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...